Product shortages are a big problem for clinical trials, because delays are bad for the patients, who may risk missing an essential treatment, as well as being hugely expensive for the company running the trial.

In 2014, a global pharmaceutical company engaged in a Phase III trial using a blockbuster oncology product in the US faced just this problem, when the manufacturer reported severe product shortages. Working with our audited and approved network of suppliers, we acted swiftly to identify a source of equivalent product from the EU, while working in parallel with the FDA in the US to ensure its approval for use.

Our customized solution and good relationships with all parties involved ensured the product was approved and imported in time, providing patients with their critical medicines and avoiding any delays to our client’s clinical trial.